Using IGF2BP3 and CENPA as biomarkers or targets to predict patients’ tumor immune microenvironment and prognosis, as well as to serve as drug targets for combination immunotherapy, is significant for the diagnosis and treatment of KIRC, providing new possibilities for precision medicine in KIRC diagnosis and treatment. Here, CENPA is linked to neoplasm.